Form 8 - Oxford Biomedica plc
Oxford Biomedica plc, as the offeree in a potential takeover situation, has disclosed that as of January 26, 2026, there are no relevant securities owned or controlled, nor any short positions or cash-settled or stock-settled derivatives held by the company itself. However, directors collectively hold 504,837 ordinary shares, representing 0.41% of the total issued share capital. Additionally, Dr. Frank Mathias holds options for 951,094 shares and 70,803 deferred bonus shares, while Dr. Lucinda Crabtree holds options for 371,208 shares and 15,733 deferred bonus shares, with various vesting and expiry dates. There are no other disclosed agreements or understandings related to inducements to deal or refrain from dealing.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
KEY INFORMATION
| (a) Full name of discloser: | Oxford Biomedica plc ("OXB") |
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree | Oxford Biomedica plc |
| (d) Is the discloser the offeror or the offeree? | Offeree |
| (e) Date position held: The latest practicable date prior to the disclosure | 26 January 2026 |
POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
| Class of relevant security: | Ordinary Shares of 50p each | |||
| Interests | Short positions | |||
| Number | % | Number | % | |
| (1) Relevant securities owned and/or controlled: | Nil | Nil | Nil | Nil |
| (2) Cash-settled derivatives: | Nil | Nil | Nil | Nil |
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | Nil | Nil | Nil | Nil |
| TOTAL: | Nil | Nil | Nil | Nil |
All interests and all short positions should be disclosed.
Rights to subscribe for new securities
| Class of relevant security in relation to which subscription right exists: | None |
| Details, including nature of the rights concerned and relevant percentages: | None |
- POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Interests of Directors OXB ordinary shares held by directors of OXB and their close relatives and related trusts Director Number of OXB ordinary shares held Percentage of total issued share capital* Dr. Roch Doliveux 438,805 0.36% Dr. Frank Mathias 20,000 0.01% Professor Dame Kay Davies 1,000 0.00% Namrata P Patel 9,170 0.00% Dr. Heather Preston 35,862 0.02% Total 504,837 0.41% *Percentages have been given to two decimal places. Interests held as options or awards by directors of OXB in ordinary shares of OXB Director Share plan Grant date Number of OXB ordinary shares in respect of which options granted / subject to award Exercise price (per share) (£) Vesting Date Date of expiry of exercise period Dr. Frank Mathias 2015 Long Term Incentive Plan* 04/10/2023 323,178 0.00 04/10/2026 04/10/2033 2024 Long Term Incentive Plan* 03/10/2024 257,113 0.00 03/10/2027 03/10/2034 2024 Long Term Incentive Plan* 16/05/2025 350,204 0.00 16/05/2028 16/05/2035 2024 Deferred Bonus Plan** 16/05/2025 70,803 0.00 T1 16/05/2026 T2 16/05/2027 T3 16/05/2028 16/05/2035 Dr. Lucinda Crabtree 2024 Long Term Incentive Plan* 03/10/2024 170,113 0.00 03/10/2027 03/10/2034 2024 Long Term Incentive Plan* 16/05/2025 201,095 0.00 16/05/2028 16/05/2035 2024 Deferred Bonus Plan** 16/05/2025 15,733 0.00 T1 16/05/2026 T2 16/05/2027 T3 16/05/2028 16/05/2035 * The vesting of the 2015 and 2024 Long Term Incentive Plan award is subject to the achievement of performance conditions and a two‑year holding period following the vesting date. ** Deferred Bonus Plan vests in three equal tranches.
- OTHER INFORMATION
- Indemnity and other dealing arrangements
None.
- Agreements, arrangements or understandings relating to options or derivatives
None.
Attachments
Are any Supplemental Forms attached?
| Supplemental Form 8 (Open Positions) | NO |
| Supplemental Form 8 (SBL) | NO |
| Date of disclosure: | 27 January 2026 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.